z-logo
Premium
Novel therapeutic regimens for urethane‐induced early lung cancer in rats: Combined cisplatin nanoparticles with vitamin‐ D 3
Author(s) -
Radwan Eman,
Ali Maha,
Faied Soad M. A.,
Omar Hossam M.,
Mohamed Wael S.,
AbdElghaffar Sary Kh.,
Sayed Ayat A.
Publication year - 2021
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.2432
Subject(s) - cisplatin , lung cancer , cancer , apoptosis , medicine , pharmacology , cancer research , treatment of lung cancer , vitamin , chemotherapy , immunology , chemistry , biochemistry
Lung cancer remains incurable; therefore, novel therapeutical approaches are of great demand. This study was designed to investigate the effectiveness of cisplatin nanoparticles combined with vitamin‐D 3 on urethane‐induced early lung cancer in rats and to clarify the underlying signaling mechanisms. Early lung cancer was induced in male Wistar rats by urethane. Rats were divided into six groups: I‐control, II‐cancer untreated, III‐cancer + free cisplatin, IV‐cancer + cisplatin nanoparticles, V‐cancer + free cisplatin + vitamin‐D 3 , VI‐cancer + cisplatin nanoparticles + vitamin‐D 3 . Inflammation, proliferation, and apoptosis were evaluated together with the levels of tumor marker CK‐19 along with histological assessment. Treatment of lung cancer with either free or nanoparticles of cisplatin alone demonstrated significant suppression in the expression of inflammatory, anti‐apoptotic and tumor markers compared to rats with lung cancer. Moreover, vitamin‐D 3 supplementation with either cisplatin forms lead to a further decrease of all markers, markedly with cisplatin nanoparticles. The present study shows the synergistic effect of cisplatin‐nanoparticles combined with vitamin‐D 3 as a new therapy regimen against lung cancer. Further studies with larger sample sizes and longer duration are needed to confirm these results.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here